Physician profile
Aju Jose
NPI 1609484633
$1,780.79
in general payments reported to CMS, 2019-2025
13 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $112 · 2024: $1,090 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,681.79 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $355.30 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $242.92 | 2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $220.44 | 2024 | Farxiga |
| Amgen INC. | $171.88 | 2023-2024 | |
| Travere Therapeutics, INC. | $149.66 | 2024 | |
| Mallinckrodt Hospital Products INC. | $144.93 | 2024 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $118.58 | 2025 | |
| Alexion Pharmaceuticals, INC. | $99.00 | 2024 | Soliris |
| Fresenius USA Marketing, INC. | $86.61 | 2024 | Nxstage System One |
| Genentech, INC. | $71.74 | 2025 | Gazyva |
| Abiomed | $61.24 | 2023 | Impella |
| Glaxosmithkline, LLC. | $38.03 | 2024 | Benlysta |
| Ambu INC. | $20.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aju Jose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.